Cosette Pharmaceuticals Announces the Approval and Launch of Metronida...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

Build community with shared future, create better world • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D • Philadelphia Works Names First Female Chief Operating Officer • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • Otr Elkalam: All the Way from Hollywood to Riyadh An American Contestant Travels to Participate in the Largest Religious Competi • Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • National University Receives 2023 Military Friendly® Gold Designation • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • Statement from the Chief Public Health Officer of Canada on World TB Day • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office

Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%

BRIDGEWATER, N.J. , February 09 /Businesswire/ - Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005033/en/

Metronidazole Gel (Photo: Business Wire)

This launch will enable Cosette to continue to build upon its unparalleled quality track record and leverage its United States based manufacturing site in Lincolnton, NC.

Apurva Saraf, President and CEO of Cosette Pharma, stated, "The continued approval and launches of our internal R&D programs highlights our commitment to world class R&D and operational excellence. We are Innovating Every Day and are committed to growing our pipeline and portfolio of products through R&D and global business development partnerships”

According to IQVIA™, U.S. market annual sales for the 12 months ended December 2022 for Metronidazole Gel USP, 1% is estimated to be approximately $17 million.

See the Full Prescribing Information and Instructions for Use for Metronidazole Gel, USP 1% at www.dailymed.com.

About Cosette Pharmaceuticals, Inc.:

Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com